KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $4.4 million.

  • CRISPR Therapeutics AG's Depreciation & Amortization (CF) fell 645.71% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year decrease of 340.11%. This contributed to the annual value of $19.3 million for FY2024, which is 291.37% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Depreciation & Amortization (CF) of $4.4 million as of Q3 2025, which was down 645.71% from $4.6 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Depreciation & Amortization (CF) peaked at $7.3 million during Q2 2022, and registered a low of $2.7 million during Q1 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $4.9 million (2023), whereas its average is $5.0 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Depreciation & Amortization (CF) soared by 14399.84% in 2021, and later crashed by 3175.13% in 2023.
  • CRISPR Therapeutics AG's Depreciation & Amortization (CF) (Quarter) stood at $6.3 million in 2021, then decreased by 6.63% to $5.8 million in 2022, then decreased by 16.18% to $4.9 million in 2023, then dropped by 1.18% to $4.8 million in 2024, then dropped by 8.45% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $4.6 million for Q2 2025, and $4.7 million during Q1 2025.